DyNAbind
Founded Year
2017Stage
Seed VC | AliveAbout DyNAbind
DyNAbind offers partnerships and solutions for drug discovery with Dynamic DNA-Encoded Library (D-DEL) technologies. The company introduces proprietary developments in library design, selection and validation, all of which lead to a faster path to high-quality, relevant starting points for medicinal chemistry – and the only DEL platform on the market fully designed to integrate with a fragment-based discovery methodology.
DyNAbind Headquarter Location
Tatzberg 47
Dresden, 01307,
Germany
Expert Collections containing DyNAbind
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
DyNAbind is included in 1 Expert Collection, including Omics.
Omics
1,265 items
Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data
Latest DyNAbind News
Sep 17, 2019
Ghent, Belgium, and Dresden, Germany – 3 July 2019 – Confo Therapeutics, an emerging drug discovery company, and DyNAbind GmbH today announce a drug discovery collaboration on an undisclosed G-protein coupled receptor (GPCR). The collaboration will combine ConfoBodyTM-enabled GPCRs with DyNAbind’s Dynamic DNA-encoded Library for the discovery of small molecule GPCR-modulating compounds. Under the terms of the agreement, Confo Therapeutics will gain exclusive, worldwide rights to any drug candidates arising from the collaboration and will be responsible for their development, manufacturing and commercialization. Commenting on the deal, Dr Christel Menet, Confo Therapeutics’ CSO, said: “This collaboration will leverage the combination of two cutting-edge technologies to expand our universe of hits on a GPCR previously thought to be intractable. We look forward to working with the DyNAbind team on this exciting project.” Dr Michael Thompson, co-founder and CEO of DyNAbind added: “GPCRs are high-potential targets for drug discovery, but have been traditionally difficult to work with. Confo Therapeutics’ technology has proven itself to be a powerful tool for the stabilization of GPCRs in a particular conformation. Partnered with the increased signal-to-noise ratios seen with our Dynamic Library technology, we are in a strong position to identify drug candidates against this specific target. ” For more information please contact: Confo Therapeutics For English-speaking and International Media: Instinctif Partners for Confo Therapeutics Dr Christelle Kerouedan, Sue Charles | + 44 (0)20 7457 2020 | confotherapeutics@instinctif.com For Belgian Media:
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.